3-phenylethynyl-4H-5-oxa-2,9b-diaza-cyclopenta[a]naphthalene

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-phenylethynyl-4H-5-oxa-2,9b-diaza-cyclopenta[a]naphthalene
• 英文别名: 3-(2-phenylethynyl)-4H-imidazo[5,1-c][1,4]benzoxazine
• 化学式: C₁₈H₁₂N₂O
• 分子量: 272.306
• InChiKey: GZHRZQIKHYTBFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-phenylethynyl-4H-5-oxa-2,9b-diaza-cyclopenta[a]naphthalene 、 碘甲烷 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以78%的产率得到1-methyl-3-phenylethynyl-4H-5-oxa-2,9b-diazacyclopenta[a]naphthalene
  参考文献：
  名称：

  Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases

  摘要：

  Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced dyskinesia in Parkinson's disease. Herein we report the optimization of a weakly active screening hit 1 to the potent and selective compounds chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, 2) and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP, 3). Compound 2 is active in a broad range of anxiety tests reaching the same efficacy but at a 10- to 100-fold lower dose compared to diazepam and is characterized by favorable DMPK properties in rat and monkey as well as an excellent preclinical safety profile and is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. Analogue 3 is the first reported mGlu5 NAM with a long half-life in rodents and is therefore an ideal tool compound for chronic studies in mice and rats.

  DOI：

  10.1021/jm501642c
• 作为产物：
  描述：

  3-iodo-4H-5-oxa-2,9b-diazacyclopenta[a]naphthalene 、 苯乙炔 在 copper(l) iodide 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以60%的产率得到3-phenylethynyl-4H-5-oxa-2,9b-diaza-cyclopenta[a]naphthalene
  参考文献：
  名称：

  Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases

  摘要：

  Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced dyskinesia in Parkinson's disease. Herein we report the optimization of a weakly active screening hit 1 to the potent and selective compounds chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, 2) and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP, 3). Compound 2 is active in a broad range of anxiety tests reaching the same efficacy but at a 10- to 100-fold lower dose compared to diazepam and is characterized by favorable DMPK properties in rat and monkey as well as an excellent preclinical safety profile and is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. Analogue 3 is the first reported mGlu5 NAM with a long half-life in rodents and is therefore an ideal tool compound for chronic studies in mice and rats.

  DOI：

  10.1021/jm501642c

文献信息

• Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
  申请人：——

  公开号：US20020128263A1

  公开（公告）日：2002-09-12

  This invention relates to a compound and the use of the compound of the formula 1 wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description, A signifies —CH═CH— or —C≡C—; and B signifies 2 wherein R 6 to R 26 , X and Y are as defined in the specification or a pharmaceutically acceptable salt thereof, for use in pharmaceutical compositions for the treatment or prevention of mGluR5 receptor mediated disorders.

  本发明涉及一种化合物及该化合物的使用，其化学式为1，其中R1、R2、R3、R4和R5如描述中所定义，A表示—CH═CH—或—C≡C—；B表示2，其中R6到R26、X和Y如规范中所定义或其药用可接受的盐，用于制备用于治疗或预防mGluR5受体介导的疾病的制药组合物。
• Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
  申请人：Recordati S.A.

  公开号：US20040215284A1

  公开（公告）日：2004-10-28

  The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agent for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal.

  本发明涉及使用选择性代谢型mGlu5受体拮抗剂治疗哺乳动物下尿路神经肌肉功能障碍的方法。本发明提供了通过施用选择性 mGlu5 拮抗剂来治疗患有下尿路神经肌肉功能障碍的哺乳动物的方法。选择性 mGlu5 拮抗剂可单独给药或与一种或多种额外的治疗剂联合给药，以治疗这种病症。还提供了鉴定选择性mGlu5拮抗剂的方法，这些选择性mGlu5拮抗剂可用于治疗哺乳动物的下尿路神经肌肉功能障碍。
• PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1349839A1

  公开（公告）日：2003-10-08
• SELECTIVE MGLU5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT
  申请人：Recordati Ireland Limited

  公开号：EP1599204A2

  公开（公告）日：2005-11-30
• US6706707B2
  申请人：——

  公开号：US6706707B2

  公开（公告）日：2004-03-16